PDF(Pubmed)
Abstract：
UNASSIGNED: Advances in targeted therapies have expanded the treatment options for colorectal cancer (CRC), allowing for more tailored and effective approaches to managing the disease. In targeted therapy, Bevacizumab is a commonly prescribed anti-VEGF monoclonal antibody that has a direct anti-vascular impact in cancer patients. Vascular Endothelial Growth Factors (VEGFs), especially VEGF-A, are significant agents in promoting tumour angiogenesis.
UNASSIGNED: To assess the impact of adding Bevacizumab to chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer.
UNASSIGNED: Comprehensive searches have been performed on electronic databases such as PubMed, and Google Scholar using the following terms: colorectal cancer, adenocarcinoma, Bevacizumab, chemotherapy, and monoclonal antibody.
UNASSIGNED: In the meta-analysis, 16 out of the 24 included studies were analysed. In the final analysis, incorporating Bevacizumab with chеmothеrapy demonstrated favourable outcomes for OS with a hazard ratio (HR = 0.689,95%CI: 0.51-0.83, I² = 39%, p <0.01) and for PFS with a hazard ratio (HR = 0.77 95% CI: 0.60-0.96, I² = 54%, p < 0.01). The subgroup analysis of PFS, categorised by study dеsign (prospеctivе vs rеtrospеctivе), reveals that the Hazard Ratio (HR = 0.82, 95% CI: 0.62-0.97, I² = 21%, p < 0.01) and for OS with a hazard ratio (HR = 0.73, 95% CI: 0.52-0.86, I² = 17%, p < 0.01).
UNASSIGNED: Our findings indicate that combining Bevacizumab with chemotherapy enhances clinical outcomes and results in a significant increase in PFS and OS in patients with metastatic colorectal cancer. Positive outcomes are demonstrated by a substantial 23% increase in PFS and 31% increase in OS in patients with metastatic colorectal cancer who undergo Bevacizumab in conjunction with chemotherapy.
UNASSIGNED: To assess the impact of adding Bevacizumab to chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer.
UNASSIGNED: Comprehensive searches have been performed on electronic databases such as PubMed, and Google Scholar using the following terms: colorectal cancer, adenocarcinoma, Bevacizumab, chemotherapy, and monoclonal antibody.
UNASSIGNED: In the meta-analysis, 16 out of the 24 included studies were analysed. In the final analysis, incorporating Bevacizumab with chеmothеrapy demonstrated favourable outcomes for OS with a hazard ratio (HR = 0.689,95%CI: 0.51-0.83, I² = 39%, p <0.01) and for PFS with a hazard ratio (HR = 0.77 95% CI: 0.60-0.96, I² = 54%, p < 0.01). The subgroup analysis of PFS, categorised by study dеsign (prospеctivе vs rеtrospеctivе), reveals that the Hazard Ratio (HR = 0.82, 95% CI: 0.62-0.97, I² = 21%, p < 0.01) and for OS with a hazard ratio (HR = 0.73, 95% CI: 0.52-0.86, I² = 17%, p < 0.01).
UNASSIGNED: Our findings indicate that combining Bevacizumab with chemotherapy enhances clinical outcomes and results in a significant increase in PFS and OS in patients with metastatic colorectal cancer. Positive outcomes are demonstrated by a substantial 23% increase in PFS and 31% increase in OS in patients with metastatic colorectal cancer who undergo Bevacizumab in conjunction with chemotherapy.
摘要：
■靶向治疗的进展扩大了结直肠癌（CRC）的治疗选择，允许更量身定制和有效的方法来管理疾病。在靶向治疗中,贝伐单抗是一种常用的抗VEGF单克隆抗体，对癌症患者具有直接的抗血管影响。血管内皮生长因子(VEGF),尤其是VEGF-A,是促进肿瘤血管生成的重要药物。
评估在转移性结直肠癌患者化疗中加入贝伐单抗对无进展生存期（PFS）和总生存期（OS）的影响。
■已在PubMed等电子数据库上进行了全面搜索，和谷歌学者使用以下术语：结直肠癌，腺癌,贝伐单抗,化疗,和单克隆抗体。
■在荟萃分析中，对24项纳入研究中的16项进行了分析。归根结底，将贝伐单抗与chomothectuderatiy合并显示出OS的有利结果，风险比（HR=0.689,95CI：0.51-0.83，I²=39％，p<0.01）和具有危险比的PFS（HR=0.7795％CI：0.60-0.96，I²=54％，p<0.01)。PFS的亚组分析，按研究符号分类(prosp市与r市)，揭示了危险比(HR=0.82，95%CI：0.62-0.97，I²=21%，p<0.01）和具有危险比的OS（HR=0.73，95%CI：0.52-0.86，I²=17%，p<0.01)。
■我们的研究结果表明，贝伐单抗联合化疗可提高转移性结直肠癌患者的临床预后，并导致PFS和OS显著增加。在接受贝伐单抗联合化疗的转移性结直肠癌患者中，PFS显着增加了23％，OS增加了31％，证明了积极的结果。
评估在转移性结直肠癌患者化疗中加入贝伐单抗对无进展生存期（PFS）和总生存期（OS）的影响。
■已在PubMed等电子数据库上进行了全面搜索，和谷歌学者使用以下术语：结直肠癌，腺癌,贝伐单抗,化疗,和单克隆抗体。
■在荟萃分析中，对24项纳入研究中的16项进行了分析。归根结底，将贝伐单抗与chomothectuderatiy合并显示出OS的有利结果，风险比（HR=0.689,95CI：0.51-0.83，I²=39％，p<0.01）和具有危险比的PFS（HR=0.7795％CI：0.60-0.96，I²=54％，p<0.01)。PFS的亚组分析，按研究符号分类(prosp市与r市)，揭示了危险比(HR=0.82，95%CI：0.62-0.97，I²=21%，p<0.01）和具有危险比的OS（HR=0.73，95%CI：0.52-0.86，I²=17%，p<0.01)。
■我们的研究结果表明，贝伐单抗联合化疗可提高转移性结直肠癌患者的临床预后，并导致PFS和OS显著增加。在接受贝伐单抗联合化疗的转移性结直肠癌患者中，PFS显着增加了23％，OS增加了31％，证明了积极的结果。
